✅ NHS-sourced information. General health information only — not personal medical advice. Always consult your GP or specialist.

Home › Health News
NICE 09 September 2026

Nemolizumab for treating moderate to severe prurigo nodularis

TA1191

📋 What this means for you AI-generated plain English summary
✓ # Nemolizumab for Treating Moderate to Severe Prurigo Nodularis
✓ What it is**: Nemolizumab is a new medicine that helps treat prurigo nodularis, a skin condition that causes itchy bumps and lesions. If you have this condition and other treatments haven't worked well, this may be an option your doctor can discuss with you.
✓ What you should do**: Talk to your dermatologist (skin doctor) about whether nemolizumab might work for your situation. This medicine is designed for people with moderate to severe cases, so it's important to see if it's right for your specific needs.
✓ Key takeaway**: This is a new treatment choice for people struggling with severe itching and skin bumps from prurigo nodularis, offering hope for those who haven't found relief with other treatments.

Always speak to your doctor before making any changes to your health or treatment.

New Guidance: NICE
View official guidance ↗

TA1191

📋 What this means for you: Speak to your GP or specialist to understand how this guidance affects your care.
Read full article on NICE ↗

This article summarises content originally published by NICE. PatientIQ provides independent plain English summaries.

More News

Free health updates

Stay one step ahead
of your condition.

New trial alerts, treatment news, and plain-English updates — matched to your condition. Free forever.

No spam. Unsubscribe anytime. Your data is private.